Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Natural innate and adaptive immunity to cancer.

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ.

Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324. Review.

PMID:
21219185
2.

Quantitative proteomics reveals subset-specific viral recognition in dendritic cells.

Luber CA, Cox J, Lauterbach H, Fancke B, Selbach M, Tschopp J, Akira S, Wiegand M, Hochrein H, O'Keeffe M, Mann M.

Immunity. 2010 Feb 26;32(2):279-89. doi: 10.1016/j.immuni.2010.01.013. Epub 2010 Feb 18.

3.

Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells.

Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Güttler S, Hutloff A, Mages HW, Ranke K, Schaefer M, Jack RS, Henn V, Kroczek RA.

Immunity. 2009 Nov 20;31(5):823-33. doi: 10.1016/j.immuni.2009.08.027. Epub 2009 Nov 12.

4.

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity.

Ishikawa H, Ma Z, Barber GN.

Nature. 2009 Oct 8;461(7265):788-92. doi: 10.1038/nature08476. Epub 2009 Sep 23.

5.

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L.

Nat Med. 2009 Oct;15(10):1170-8. doi: 10.1038/nm.2028. Epub 2009 Sep 20.

PMID:
19767732
6.

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.

Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF.

Cancer Res. 2009 Apr 1;69(7):3077-85. doi: 10.1158/0008-5472.CAN-08-2281. Epub 2009 Mar 17.

7.

Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM.

Science. 2008 Nov 14;322(5904):1097-100. doi: 10.1126/science.1164206.

8.

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.

Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF.

Clin Cancer Res. 2008 May 15;14(10):3156-67. doi: 10.1158/1078-0432.CCR-07-4696.

9.

Extracellular NAD and ATP: Partners in immune cell modulation.

Haag F, Adriouch S, Braß A, Jung C, Möller S, Scheuplein F, Bannas P, Seman M, Koch-Nolte F.

Purinergic Signal. 2007 Mar;3(1-2):71-81. doi: 10.1007/s11302-006-9038-7. Epub 2007 Jan 9.

10.

Autoantibodies to tumor-associated antigens: reporters from the immune system.

Tan EM, Zhang J.

Immunol Rev. 2008 Apr;222:328-40. doi: 10.1111/j.1600-065X.2008.00611.x. Review.

11.

How dying cells alert the immune system to danger.

Kono H, Rock KL.

Nat Rev Immunol. 2008 Apr;8(4):279-89. doi: 10.1038/nri2215. Epub 2008 Mar 14. Review.

12.

Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes.

Fortunato G, Calcagno G, Bresciamorra V, Salvatore E, Filla A, Capone S, Liguori R, Borelli S, Gentile I, Borrelli F, Borgia G, Sacchetti L.

J Interferon Cytokine Res. 2008 Mar;28(3):141-52. doi: 10.1089/jir.2007.0049.

PMID:
18338947
13.

Equilibrium between host and cancer caused by effector T cells killing tumor stroma.

Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H.

Cancer Res. 2008 Mar 1;68(5):1563-71. doi: 10.1158/0008-5472.CAN-07-5324.

14.

Migration of dendritic cell subsets and their precursors.

Randolph GJ, Ochando J, Partida-Sánchez S.

Annu Rev Immunol. 2008;26:293-316. Review.

PMID:
18045026
15.

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L.

Nat Med. 2007 Sep;13(9):1050-9. Epub 2007 Aug 19.

PMID:
17704786
16.

DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response.

Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, Taniguchi T.

Nature. 2007 Jul 26;448(7152):501-5. Epub 2007 Jul 8.

PMID:
17618271
17.

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.

Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA.

J Immunol. 2007 Feb 1;178(3):1268-76. Erratum in: J Immunol. 2007 Nov 15;179(10):7184.

18.

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H.

J Exp Med. 2007 Jan 22;204(1):49-55. Epub 2007 Jan 8.

19.

Immunosuppressive strategies that are mediated by tumor cells.

Rabinovich GA, Gabrilovich D, Sotomayor EM.

Annu Rev Immunol. 2007;25:267-96. Review.

20.

Interferons, immunity and cancer immunoediting.

Dunn GP, Koebel CM, Schreiber RD.

Nat Rev Immunol. 2006 Nov;6(11):836-48. Review.

PMID:
17063185
Items per page

Supplemental Content

Write to the Help Desk